WallStSmart

Cencora Inc. (COR)vsHenry Schein Inc (HSIC)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Cencora Inc. generates 2357% more annual revenue ($337.40B vs $13.73B). HSIC leads profitability with a 3.1% profit margin vs 1.0%. COR appears more attractively valued with a PEG of 0.77. COR earns a higher WallStSmart Score of 62/100 (C+).

COR

Buy

62

out of 100

Grade: C+

Growth: 6.0Profit: 6.0Value: 5.3Quality: 3.8
Piotroski: 5/9

HSIC

Buy

53

out of 100

Grade: C-

Growth: 5.3Profit: 5.5Value: 6.7Quality: 5.0
Piotroski: 2/9Altman Z: 2.37
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

CORSignificantly Overvalued (-85.6%)

Margin of Safety

-85.6%

Fair Value

$193.43

Current Price

$359.03

$165.60 premium

UndervaluedFair: $193.43Overvalued
HSICUndervalued (+48.0%)

Margin of Safety

+48.0%

Fair Value

$157.15

Current Price

$84.96

$72.19 discount

UndervaluedFair: $157.15Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

COR4 strengths · Avg: 8.8/10
Return on EquityProfitability
94.6%10/10

Every $100 of equity generates 95 in profit

Market CapQuality
$66.67B9/10

Large-cap with strong market position

PEG RatioValuation
0.778/10

Growing faster than its price suggests

Free Cash FlowQuality
$2.70B8/10

Generating 2.7B in free cash flow

HSIC2 strengths · Avg: 8.0/10
Price/BookValuation
3.0x8/10

Reasonable price relative to book value

EPS GrowthGrowth
26.2%8/10

Earnings expanding 26.2% YoY

Areas to Watch

COR4 concerns · Avg: 2.8/10
Price/BookValuation
18.6x4/10

Trading at 18.6x book value

Profit MarginProfitability
1.0%3/10

1.0% margin — thin

Operating MarginProfitability
1.4%3/10

Operating margin of 1.4%

Debt/EquityHealth
3.061/10

Elevated debt levels

HSIC4 concerns · Avg: 3.5/10
PEG RatioValuation
1.734/10

Expensive relative to growth rate

Revenue GrowthGrowth
4.0%4/10

4.0% revenue growth

Profit MarginProfitability
3.1%3/10

3.1% margin — thin

Debt/EquityHealth
1.233/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : COR

The strongest argument for COR centers on Return on Equity, Market Cap, PEG Ratio. PEG of 0.77 suggests the stock is reasonably priced for its growth.

Bull Case : HSIC

The strongest argument for HSIC centers on Price/Book, EPS Growth.

Bear Case : COR

The primary concerns for COR are Price/Book, Profit Margin, Operating Margin. Debt-to-equity of 3.06 is elevated, increasing financial risk. Thin 1.0% margins leave little buffer for downturns.

Bear Case : HSIC

The primary concerns for HSIC are PEG Ratio, Revenue Growth, Profit Margin. Thin 3.1% margins leave little buffer for downturns.

Key Dynamics to Monitor

HSIC carries more volatility with a beta of 0.86 — expect wider price swings.

COR is growing revenue faster at 5.5% — sustainability is the question.

COR generates stronger free cash flow (2.7B), providing more financial flexibility.

Monitor MEDICAL DISTRIBUTION industry trends, competitive dynamics, and regulatory changes.

Bottom Line

COR scores higher overall (62/100 vs 53/100). HSIC offers better value entry with a 48.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Cencora Inc.

HEALTHCARE · MEDICAL DISTRIBUTION · USA

CoreSite Realty Corporation (NYSE: COR) delivers secure, reliable, high-performance data center, cloud access and interconnect solutions to a growing client ecosystem in eight key North American markets.

Henry Schein Inc

HEALTHCARE · MEDICAL DISTRIBUTION · USA

Henry Schein, Inc. is an American distributor of health care products and services with a presence in 32 countries.

Visit Website →

Want to dig deeper into these stocks?